摘要
目的探讨氯呲格雷联合瑞舒伐他汀治疗2型糖尿病合并急性冠脉综合征(ACS)的临床效果。方法临床纳入该院2015年4月—2017年6月期间收治的60例2型糖尿病合并ACS患者作为研究对象,根据不同治疗方案平分为研究组、对照组,均为30例。对照组单纯给予氯呲格雷进行治疗,研究组在氯呲格雷基础上给予瑞舒伐他汀进行联合干预,并将两组治疗前后ET-1、TNF-α、IL-1等指标及不良反应发生率进行对比。结果研究组与对照组患者治疗前ET-1、TNF-α、IL-1对比差异无统计学意义;治疗后研究组ET-1、TNF-α、IL-1等指标均明显优于对照组(t=-2.745、P=0.008,t=-10.683、P=0.000,t=-4.209、P=0.000);研究组治疗期间不良反应发生率为6.67%,对照组不良反应发生率为3.33%,组间对比差异无统计学意义(χ~2=1.174、P=0.279)。结论相较于单一用药,在氯呲格雷治疗基础上联合瑞舒伐他汀对2型糖尿病合并ACS患者进行治疗效果更优,且无明显不良反应,用药安全性较高,具备临床意义与运用价值。
Objective To analyze the c lin ica l effect of clopidogrel and rosuvastatin calcium in treatment of type 2 diabetes and acute Coronary syndrome. Methods 60 cases of patients with type 2 diabetes and ACS admitted and treated in our hos-pital from April 2015 to June 2017 were selected as the research objects and divided into two groups according to different treatment plans, with 30 cases in each, the control group were treated with simple clopidogrel, while the research group were treated with clopidogrel and rosuvastatin calcium, and the ET-1,TNF-α, IL-1 and incidence rate of adverse reactions of the two groups were compared before and after treatment. Results The differences in the E T -1 , TNF-α, IL -1 between the two groups before treatment were not statistically significant, after treatment, the ET-1,TNF-α,IL-1 in the research group after treatment were obviously better than those in the control group （t = -2 .745 , P = 0 .008 , t = -10 .683 , P = 0 .000 , t = - 4.209, P=0.000）, and the incidence rate of adverse reactions in the research group and in the control group was respectively 6.67% and 3.33%, and the differences were statistically significant,（X^2=1.174, P = 0 .279 ） . Conclusion The effect of clopidogrel and rosuvastatin calcium in treatment of type 2 diabetes and acute coronary syndrome is better than that of simple medication, without obvious toxic and side effects and the medication safety is high, and it is of great clinical significance and application value.
出处
《糖尿病新世界》
2017年第18期16-17,共2页
Diabetes New World Magazine
